StayCurrentMD · Early vasopressor administration in pediatric blunt liver and spleen injury: An ATOMAC+ study
Article1 min read·Published Aug 2020Older

Early vasopressor administration in pediatric blunt liver and spleen injury: An ATOMAC+ study

jpedsurg.org shows its articles on its own site.

Read the article on jpedsurg.org ↗

Article · Aug 2020 · 1 min read

In brief

In brief

Multicenter prospective study of 1004 children with blunt liver/spleen injuries found early vasopressor use (<48h) associated with 7-11 fold increased mortality risk but no impact on nonoperative management failure. All vasopressor-related deaths occurred within 12 hours of injury, highlighting critical early resuscitation challenges in pediatric abdominal trauma.

Written by the GCMD Library team from the article.

Abstract

Background

No prior studies have examined the outcomes of early vasopressor use in children sustaining blunt liver or spleen injury (BLSI).

Methods

A planned secondary analysis of vasopressor use from a 10-center, prospective study of 1004 children with BLSI. Inverse probability of treatment weighting (IPTW) was used to compare patients given vasopressors <48 h after injury to controls based on pretreatment factors. A logistic regression was utilized to assess survival associated with vasopressor initiation factors on mortality and nonoperative management (NOM) failure.

Results

Of 1004 patients with BLSI, 128 patients were hypotensive in the Pediatric Trauma Center Emergency Department (ED); 65 total patients received vasopressors. Hypotension treated with vasopressors was associated with a sevenfold increase in mortality (AOR = 7.6 [p < 0.01]). When excluding patients first given vasopressors for cardiac arrest, the risk of mortality increased to 11-fold (AOR = 11.4 [p = 0.01]). All deaths in patients receiving vasopressors occurred when started within the first 12 h after injury. Vasopressor administration at any time was not associated with NOM failure.

Conclusion

After propensity matching, early vasopressor use for hypotension in the ED was associated with an increased risk of death, but did not increase the risk of failure of NOM.

Level of evidence

Level III prognostic and epidemiological, prospective.

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →